Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2020-10-01 Annual Report
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 68 pages 928.0KB
Annual Report Classification · 100% confidence The document is titled 'STATUTORY ANNUAL REPORT 2020' and includes detailed sections such as Directors' Report, Remuneration Report, Corporate Governance, Senior Management, Operating and Financial Review and Prospects, and comprehensive Financial Statements including income statement, balance sheet, cash flows, notes, auditor's report, and shareholder information. It is lodged with the Australian Securities Exchange and the Australian Securities and Investments Commission, indicating it is an official annual report. The length is substantial (15,000 characters), and it contains actual financial data and detailed management discussion. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2020-10-01 English
Notice of Annual General Meeting/Proxy Form 19 pages 1.5MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF THE 2020 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and details the arrangements for the company's 2020 AGM, including the date, time, virtual meeting instructions, agenda items such as financial statements, remuneration report, director re-elections, and grant of securities. It includes proxy voting instructions and voting restrictions. The document is a notice and explanatory statement for the AGM, not the actual AGM materials or minutes, nor the financial reports themselves. It is a formal notice to shareholders about the upcoming AGM and the business to be conducted there. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), consistent with a detailed AGM notice and explanatory statement, not a brief announcement or proxy solicitation only.
2020-10-01 English
Appendix 4G 14 pages 187.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and is described as a 'Key to Disclosures Corporate Governance Council Principles and Recommendations.' It references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures for entities listed on the Australian Securities Exchange (ASX). The document includes detailed tables showing compliance with corporate governance principles and recommendations, with references to where disclosures can be found (e.g., URLs to the company's website). It is explicitly stated that this Appendix 4G is lodged with the ASX alongside the annual report but is not a substitute for the corporate governance statement itself. The content is focused on governance practices, board charters, diversity policies, evaluation processes, and committee structures, rather than financial results or management changes. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is not an announcement or a brief notice but a substantive governance disclosure document. Therefore, the appropriate classification is CGR with high confidence.
2020-10-01 English
Corporate Governance Statement 19 pages 199.4KB
Governance Information Classification · 100% confidence The document is titled 'Copy of Corporate Governance Statement – 2020' and contains detailed descriptions of the company's corporate governance framework, board structure, policies, and practices. It references the ASX Corporate Governance Principles and Recommendations and discusses board roles, diversity policies, performance evaluations, and committee charters. There is no financial data, earnings information, or audit results presented. The content is focused on governance practices and disclosures rather than financial performance or regulatory filings. Therefore, this document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is a full governance report, not a brief announcement or certification.
2020-10-01 English
Appendix 2A - exercise of employee options 15 pages 198.4KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of securities due to options being exercised or convertible securities being converted. The document is a formal announcement to the exchange regarding the quotation of new securities, not a financial report or earnings release. It is regulatory in nature, related to capital market activities but specifically about the quotation of securities rather than a financing update or capital structure change announcement. This type of document fits best under the category of Regulatory Filings (RNS) as it is a compliance announcement to the exchange and does not contain financial statements or detailed financial analysis. The document length is 15,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2020-09-30 English
Appendix 2A - Exercise of Employee Options 15 pages 198.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A' and is an 'Application for quotation of securities' submitted to the ASX (Australian Securities Exchange). It contains detailed information about the entity (Pharmaxis Ltd), the type of securities being quoted (options exercised or convertible securities converted), dates, and compliance with ASX listing rules. This type of document is a formal announcement related to the issuance and quotation of new securities on the exchange, which aligns with announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or voting results. The document is a regulatory announcement about capital changes, specifically the quotation of new securities following option exercises. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief notice or a report publication announcement but a substantive filing about capital changes.
2020-09-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.